TIRmed’s TIR‑C: Advancing Topical Oligonucleotide Therapy for Atopic Dermatitis into the Clinic
Time: 11:00 am
day: Day Two AM
Details:
- TIR‑C aims to relieve itch and regenerate tissue without systemic side effects, thereby directly modulating skin immune cells (e.g., dendritic, mast cells, IL‑10 induction)
- Outlining nonclinical toxicology and regulatory approaches for CTA approval ahead of planned Phase I trial in 2026
- After Phase I safety and tolerability results TIRmed will prepare for Phase Ib targeting efficacy in mild-to-moderate AD positioning the program as a second line treatment after corticosteroids
